Follicular Lymphoma

Follicular lymphoma (FL) is the most common type of the slow growing non-Hodgkin’s lymphomas. FL is derived from germinal center B cells and acquire genetic changes to develop into a malignant phenotype. BCR and its pathways appear to contribute to the survival of malignant cells.

FL accounts for one-third of non-Hodgkin lymphomas in adults. Median age at diagnosis is 60 years. This lymphoma usually responds well to initial treatment but is prone to relapses, sometimes transforming into high-grade NHL. The prognosis for individual patients can be estimated using the Follicular Lymphoma International Prognostic Index (FLIPI). Follicular lymphoma is not usually curable with conventional treatment. All patients usually receive rituximab as part of their treatment. However more patients are becoming rituximab refractory which has led to the research and development of new therapeutic agents.

iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al.
2:31
Chemotherapy-free approaches in CLL, follicular lymphoma and DLBCL
Christian Buske
2:23
The GALLIUM study
Robert Marcus
3:02
What are the causes of fatigue after cancer treatment?
Marije van der Lee
3:21
Holistic care in the management of asymptomatic follicular lymphoma
George Follows
4:31
Overview of the GALLIUM study
Wolfgang Hiddemann
2:49
Overview of classical therapies for follicular lymphoma
Andrew Lister
4:14
Novel therapies for the treatment of CLL, MCL and FL
Nathan Fowler
1:55
Ibrutinib in combination with rituximab – the future of treating FL
Nathan Fowler
1:53
Relapsed follicular lymphoma: hope from a non-chemotherapy regimen of lenalidomide and obinutuzumab
Nathan Fowler
2:46
Is obinutuzumab our key to improving the treatment of FL?
Wolfgang Hiddemann
1:26
Clinicogenetic risk models to predict outcome of follicular lymphoma patients
Sarah Huet
4:02
Key therapeutic advances in follicular lymphoma
Andrew Davies
1:01
Using models to predict progression in follicular lymphoma
Sarah Huet
2:53
Comparing the efficacy and safety of CT-P10 to rituximab in advanced stages follicular lymphoma
Christian Buske
2:07
Copanlisib produces promising results in relapsed/refractory follicular lymphoma
George Follows
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals